Key result
Head and neck cancer linked to ~38% greater MI risk and higher stroke risk.
Why the study?
Various treatment modalities are used for head and neck cancer, but the incidence and risks of myocardial infarction and stroke by cancer site and treatment modality needed analysis.
Does head and neck cancer and its treatment modalities increase the risk of myocardial infarction and stroke compared to patients without HNC?
Population
22,737 newly diagnosed HNC patients and 68,211 controls in the Korean National Health Insurance Service database
Comparison
HNC patients vs controls without HNC, stroke, or MI, and by cancer site and treatment modality
Design
Retrospective database cohort study
Authors
Loading...
May support closer CV surveillance in HNC; leaves open whether cancer or therapies drive risk, warranting prospective studies.
Cohort (n=90,948)
Does head and neck cancer and its treatment modalities increase the risk of myocardial infarction and stroke compared to patients without HNC?
Hazard Ratio: 1.38 (95% CI 1.24–1.53)
Absolute Event Rate: 4.42% vs 3.39%
p-value: p=<0.05
Patients with head and neck cancer, particularly those receiving chemotherapy, have a significantly increased risk of myocardial infarction, stroke, and mortality compared to controls.
Kwon et al. (2021) conducted a cohort in Head and neck cancer (n=90,948). Head and neck cancer vs. Matched non-cancer controls was evaluated on Myocardial infarction (HR 1.38, 95% CI 1.24-1.53, p=<0.05). Patients with head and neck cancer had a significantly higher risk of myocardial infarction (HR 1.38) and stroke (HR 1.48) compared to a matched non-cancer control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: